VTE-3 VTE Patients with Anticoagulation Overlap Therapy

This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they must be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy must be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy. 

 

Measure Steward

The Joint Commission

 

Measure Numerator

Patients who received overlap therapy (warfarin and parenteral anticoagulation):
• 5 or more days, with an INR greater than or equal to 2 prior to discontinuation of parenteral therapy,
OR
• 5 or more days, with an INR less than 2 and discharged on overlap therapy,
OR
• Less than 5 days and discharged on overlap therapy,
OR
• With documentation of reason for discontinuation of overlap therapy,
OR
• With documentation of a reason for no overlap therapy

 

Measure Denominator

Patients with confirmed VTE who received warfarin.